سامانه مدیریت نشریات علمی دانشگاه علوم پزشکی مشهد

Kim, Jin Suk, Park, Shin Young. (1393). 18F-FDG PET/CT of advanced gastric carcinoma and association of HER2 expression with standardized uptake value. , 2(1), 12-18. doi: 10.7508/aojnmb.2014.01.003
Jin Suk Kim; Shin Young Park. "18F-FDG PET/CT of advanced gastric carcinoma and association of HER2 expression with standardized uptake value". , 2, 1, 1393, 12-18. doi: 10.7508/aojnmb.2014.01.003
Kim, Jin Suk, Park, Shin Young. (1393). '18F-FDG PET/CT of advanced gastric carcinoma and association of HER2 expression with standardized uptake value', , 2(1), pp. 12-18. doi: 10.7508/aojnmb.2014.01.003
Kim, Jin Suk, Park, Shin Young. 18F-FDG PET/CT of advanced gastric carcinoma and association of HER2 expression with standardized uptake value. , 1393; 2(1): 12-18. doi: 10.7508/aojnmb.2014.01.003

18F-FDG PET/CT of advanced gastric carcinoma and association of HER2 expression with standardized uptake value

Asia Oceania Journal of Nuclear Medicine and Biology
مقاله 3، دوره 2، شماره 1، مرداد 2014، صفحه 12-18    اصل مقاله (1.5 M)
نوع مقاله: Original Article
شناسه دیجیتال (DOI): 10.7508/aojnmb.2014.01.003
نویسندگان
Jin Suk Kim1؛ Shin Young Park* 2
1Department of Nuclear Medicine, Konyang University College of Medicine, Daejeon, Korea
2Department of Pathology, Konyang University College of Medicine, Daejeon, Korea
چکیده
Objective(s): Expression of HER2 in gastric carcinoma has direct prognostic and therapeutic implications in patient management. The aim of this study is to determine whether a relationship exists between standardized uptake value
(SUV) and expression of HER2 in advanced gastric carcinoma.
Methods: We analyzed the 18F-FDG PET/CT results of 109 patients that underwent gastrectomy for advanced gastric carcinoma. The 18F-FDG PET/CT imaging was requested at the initial staging before surgery. The examinations were evaluated semi-quantitatively, with calculation of maximum standardized uptake values (SUVmax). The clinicopathologic factors, including HER2 overexpression, were determined from tissue obtained from the primary tumor.
Metabolic and clincopathologic parameters were correlated using a t-test, one way ANOVA and chi-square test.
Results: Immunohistochemically, 26 patients (23.8%) showed HER2 overexpression. This overexpression was significantly associated with high SUV level (P=0.02). The SUV level was significantly correlated with tumor size
(P=0.02) and differentiation (P<0.001), and Lauren histologic type (P=0.04).
Multivariate analysis showed HER2 overexpression, large tumor size, and differentiation (P=0.022, P=0.002, P<0.001) were significantly correlated with the high level of SUV in advanced gastric carcinoma. No association was found between SUV and T stage and lymph node metastasis. A receiver-operating characteristic curve demonstrated a SUVmax of 3.5 to be the optimal cutoff for predicting HER2 overexpression (sensitivity; 76.9%, specificity; 60.2%).
Conclusion: An association exists between high SUV and HER2 overexpression and 18F-FDG PET/CT could be a useful tool to predict the biological characteristics of gastric carcinoma.
کلیدواژه‌ها
Advanced gastric carcinoma؛ HER2؛ PET-CT
مراجع
  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127(12):2893-917.
  2. Park JM, Kim YH. Current approaches to gastric cancer in Korea. Gastrointest Cancer Res. 2008; 2(3):137-44.
  3. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene. 1990; 5(7):953-62.
  4. Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007; 26(45): 6469-87.
  5. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009; 14(4):320-68.
  6. Jorgensen JT, Nielsen KV, Ejlertsen B. Pharmaco-diagnostics and targeted therapies - a rational approach for individualizing medical anticancer therapy in breast cancer. Oncologist. 2007; 12(4):397-405.
  7. Bongiorno PF, Whyte RI, Lesser EJ, Moore JH, Orringer MB, Beer DG. Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarci-nomas. J Thorac Cardiovasc Surg. 1994; 107(2): 590-5.
  8. Morris MJ, Reuter VE, Kelly WK, Slovin SF, Kenneson K, Verbel D, et al. HER-2 profiling and targeting in prostate carcinoma. Cancer. 2002; 94(4): 980-6.
  9. Schuell B, Gruenberger T, Scheithauer W, Zielinski C, Wrba F. HER 2/neu protein expre-ssion in colorectal cancer. BMC Cancer. 2006; 6:123.
  10. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemo-therapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, random-ised controlled trial. Lancet. 2010; 376(9742): 687-97.
  11. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008; 49(3):480-508.
  12. Edge SB BD, Compton CC, Fritz AG, Greene FL, Trotti A, editor. AJCC cancer staging manual 7ed: New York, NY: Springer; 2010.
  13. Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, et al. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomog-raphy/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol. 2008; 38(4):250-8.
  14. Kawamura T, Kusakabe T, Sugino T, Watanabe K, Fukuda T, Nashimoto A, et al. Expression of glucose transporter-1 in human gastric carcin-oma: association with tumor aggressiveness, metastasis, and patient survival. Cancer. 2001; 92(3): 634-41.
  15. Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging. 2003; 30(2):288-95.
  16. Han EJ CW, Chung YA et al. Comparision between FDG uptake and clinicopathologic and immun-ohistochemical parameters in pre-operative PET/CT Scan of primary gastric carcinoma. Nucl Med Mol Imaging. 2009; 42(1):26-34.
  17. Kim WS KY, Jang SJ, Kimm K, Jung MH. Glucose transporter 1 (GLUT1) expression is associated with intestinal type of gastric carcinoma. J Korean Med Sci. 2000; 15:420-4.
  18. Yamada A, Oguchi K, Fukushima M, Imai Y, Kadoya M. Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression. Ann Nucl Med. 2006; 20(9): 597-604.
  19. Oh HH, Lee SE, Choi IS, Choi WJ, Yoon DS, Min HS, et al. The peak-standardized uptake value (P-SUV) by preoperative positron emission tomography-computed tomography (PET-CT) is a useful indicator of lymph node metastasis in gastric cancer. J Surg Oncol. 2011; 104(5):530-3.
  20. Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K. Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg. 2004; 28(3):247-53.
  21. Lastraioli E, Romoli MR, Arcangeli A. Immunohistochemical biomarkers in gastric cancer research and management. Int J Surg Oncol. 2012; 2012:868645.
  22. Dang HZ, Yu Y, Jiao SC. Prognosis of HER2 over-expressing gastric cancer patients with liver metastasis. World J Gastroenterol. 2012; 18(19): 2402-7.
  23. Sakai K, Mori S, Kawamoto T, Taniguchi S, Kobori O, Morioka Y, et al. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst. 1986; 77(5):1047-52.
  24. Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review. Int J Cancer. 2012; 130(12):2845-56.
  25. Jorgensen JT HM. HER2 as a prognostic marker in gastric cancer - A systematic analysis of data from the literature. J Cancer. 2012; 3:137-44.
آمار
تعداد مشاهده مقاله: 3,208
تعداد دریافت فایل اصل مقاله: 2,751